Institutional Ownership
Elicio Therapeutics Inc
CUSIP 28657F103COMELTXQ1 2026
13D / 13G Filings
18
Schedule 13D/13G on record
Beneficial Filers
7
Distinct reporting persons
Largest Stake
48.1%
Max % of class reported
Institutional Holders
44
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
18 filings · latest Oct 7, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Oct 7, 2025 | Actyus Private Equity Sgiic, S.A. | 13G/A | 1.6% | — | SEC |
| 2 | Jun 4, 2025 | Gkcc, LLC | 13D/A | 48.0% | — | SEC |
| 3 | May 14, 2025 | Actyus Private Equity Sgiic, S.A. | 13G/A | 5.4% | — | SEC |
| 4 | Mar 7, 2025 | Yekaterina Chudnovsky | 13D/A | 48.1% | — | SEC |
| 5 | Feb 5, 2025 | Knoll Capital Management, LLC | 13G | 5.2% | 630.9K | SEC |
| 6 | Jan 7, 2025 | Actyus Private Equity Sgiic, S.A. | 13G | 5.5% | — | SEC |
| 7 | Aug 14, 2024 | Gkcc, LLC | 13D/A | 38.7% | 5.60M | SEC |
| 8 | Jul 2, 2024 | Gkcc, LLC | 13D/A | 20.0% | 2.15M | SEC |
| 9 | Apr 10, 2024 | Clal Biotechnology Industries Ltd. | 13D/A | 4.7% | 481.7K | SEC |
| 10 | Mar 20, 2024 | Clal Biotechnology Industries Ltd. | 13D/A | 5.8% | 599.2K | SEC |
8 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Elicio Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Knoll Capital Management, LLC | 630.9K | $6.74M |
| 2 | Balyasny Asset Management L.P. | 244.8K | $2.62M |
| 3 | Geode Capital Management, LLC | 135.2K | $1.45M |
| 4 | Renaissance Technologies LLC | 121.6K | $1.30M |
| 5 | Millennium Management LLC | 92.8K | $991.6K |
| 6 | Marshall Wace, LLP | 74.5K | $796.5K |
| 7 | Susquehanna International Group, LLP | 70.8K | $756.9K |
| 8 | Northern Trust Corp | 59.7K | $638.6K |
| 9 | Goldman Sachs Group Inc | 57.8K | $618.1K |
| 10 | 683 Capital Management, LLC | 56.4K | $603.4K |